Literature DB >> 10703923

Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide.

Y Sakuma1, K Tanaka, M Suda, A Yasoda, K Natsui, I Tanaka, F Ushikubi, S Narumiya, E Segi, Y Sugimoto, A Ichikawa, K Nakao.   

Abstract

Prostaglandin E2 (PGE2) exerts its effects through the PGE receptor that consists of four subtypes (EP1, EP2, EP3, and EP4). Osteoclast formation in the coculture of primary osteoblastic cells (POB) and bone marrow cells was enhanced more by 11-deoxy-PGE1 (an EP4 and EP2 agonist) than by butaprost (an EP2 agonist) and other agonists, which suggests that EP4 is the main factor in PGE2-induced osteoclast formation. PGE2-induced osteoclast formation was not observed in the coculture of POB from EP4-deficient (EP4 k/o) mice and spleen cells from wild-type (w/t) mice, whereas osteoclasts were formed in the coculture of POB from w/t mice and spleen cells from EP4-k/o mice. In situ hybridization (ISH) showed that EP4 messenger RNA (mRNA) was expressed on osteoblastic cells but not on multinucleated cells (MNCs) in w/t mice. These results indicate that PGE2 enhances osteoclast formation through its EP4 subtype on osteoblasts. Osteoclast formation by interleukin 1alpha (IL-1alpha), tumor necrosis factor alpha (TNF-alpha), basic fibroblast growth factor (bFGF), and lipopolysaccharide (LPS) was hardly observed in the coculture of POB and bone marrow cells, both from EP4-k/o mice, which shows the crucial involvement of PG and the EP4 subtype in osteoclast formation by these molecules. In contrast, osteoclast formation by 1,25-hydroxyvitamin D3 (1,25(OH)2D3) was not impaired and that by parathyroid hormone (PTH) was only partially impaired in EP4-k/o mice, which may be related to the fact that EP4-k/o mice revealed no gross skeletal abnormalities. Because it has been suggested that IL-1alpha, TNF-alpha, bFGF, and LPS are involved in inflammatory bone loss, our work can be expected to contribute to an understanding of the pathophysiology of these conditions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10703923     DOI: 10.1359/jbmr.2000.15.2.218

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  19 in total

Review 1.  Genetic and pharmacological analysis of prostanoid receptor function.

Authors:  S Narumiya; G A FitzGerald
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

2.  In vivo effects of two novel ALN-EP4a conjugate drugs on bone in the ovariectomized rat model for reversing postmenopausal bone loss.

Authors:  S Hu; C C Liu; G Chen; T Willett; R N Young; M D Grynpas
Journal:  Osteoporos Int       Date:  2015-08-14       Impact factor: 4.507

3.  The cytolethal distending toxin induces receptor activator of NF-kappaB ligand expression in human gingival fibroblasts and periodontal ligament cells.

Authors:  G N Belibasakis; A Johansson; Y Wang; C Chen; S Kalfas; U H Lerner
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

4.  An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption.

Authors:  B S Herrera; T Ohira; L Gao; K Omori; R Yang; M Zhu; M N Muscara; C N Serhan; T E Van Dyke; R Gyurko
Journal:  Br J Pharmacol       Date:  2008-09-22       Impact factor: 8.739

5.  Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation.

Authors:  Keiji Yoshida; Hiroji Oida; Takuya Kobayashi; Takayuki Maruyama; Masaharu Tanaka; Teruaki Katayama; Kojiro Yamaguchi; Eri Segi; Tadao Tsuboyama; Mutsumi Matsushita; Kosei Ito; Yoshiaki Ito; Yukihiko Sugimoto; Fumitaka Ushikubi; Shuichi Ohuchida; Kigen Kondo; Takashi Nakamura; Shuh Narumiya
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

6.  The growth of malignant keratinocytes depends on signaling through the PGE(2) receptor EP1.

Authors:  E J Thompson; A Gupta; G A Vielhauer; J W Regan; G T Bowden
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

7.  Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype.

Authors:  Y Sakuma; K Tanaka; M Suda; Y Komatsu; A Yasoda; M Miura; A Ozasa; S Narumiya; Y Sugimoto; A Ichikawa; F Ushikubi; K Nakao
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

Review 8.  Prostaglandin E2 and IL-23 interconnects STAT3 and RoRγ pathways to initiate Th17 CD4+ T-cell development during rheumatoid arthritis.

Authors:  Janaiya S Samuels; Lauren Holland; María López; Keya Meyers; William G Cumbie; Anna McClain; Aleksandra Ignatowicz; Daryllynn Nelson; Rangaiah Shashidharamurthy
Journal:  Inflamm Res       Date:  2018-04-30       Impact factor: 4.575

9.  Resolvin E1 Inhibits Osteoclastogenesis and Bone Resorption by Suppressing IL-17-induced RANKL Expression in Osteoblasts and RANKL-induced Osteoclast Differentiation.

Authors:  Yoshihiro Funaki; Yasuyuki Hasegawa; Ryota Okazaki; Akira Yamasaki; Yuriko Sueda; Akihiro Yamamoto; Masaaki Yanai; Takehito Fukushima; Tomoya Harada; Haruhiko Makino; Eiji Shimizu
Journal:  Yonago Acta Med       Date:  2018-03-28       Impact factor: 1.641

10.  The remarkable mechanism of prostaglandin E2 on synaptic plasticity.

Authors:  Yukio Akaneya
Journal:  Gene Regul Syst Bio       Date:  2008-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.